Everything a new member needs before diving into the Lab.

A space for step-by-step demonstrations, visual walkthroughs, and practical research education. Videos may cover classroom navigation, terminology, tracking, research files, blood work, and other helpful topics as the lab grows.

Before beginning any research protocol, it's important to understand where you're starting. A baseline isn't just one lab value, it's a snapshot of your overall health at a single point in time. Establishing a baseline allows you to compare future changes and better understand whether those changes may be related to your research protocol, natural biological variation, or another underlying factor.

Not sure where to begin? The Research Roadmap helps you start with your goal, explore different areas of research, and find the Research Files that may be most relevant to what you want to learn. Use it as your guide through the Lab, without the overwhelm.

A quick-reference guide to commonly discussed peptides and peptide-based compounds. Each entry explains what it is, what researchers are studying it for, and whether a full SubZ course is available. This glossary is educational only and does not replace medical care, individualized guidance, or product verification.

Open the file on semaglutide, a synthetic GLP-1 peptide analog studied for metabolic health, blood-sugar regulation, appetite, body weight, and cardiovascular outcomes. Explore how the peptide was designed, how it communicates with GLP-1 receptors, what human research shows, and where evidence ends and internet hype begins. Educational only. Not medical advice or an individualized recommendation.

Explore the science behind tirzepatide through a research-first approach. This Clinical Research File examines how tirzepatide works, the dual GIP and GLP-1 pathways it targets, major clinical trials, dosing protocols used in research, safety considerations, and current evidence. Learn how to evaluate the research, understand the mechanisms, and separate published data from online hype.

Explore retatrutide through SubZ’s research-first approach. This file examines its triple GIP, GLP-1 and glucagon receptor activity, published clinical evidence, protocols used in human trials, side effects, safety considerations and what to track. Retatrutide remains investigational, so this course clearly separates verified trial data from unapproved products and online claims.

Explore KPV through SubZ’s research-first approach. This file examines the three-amino-acid fragment of alpha-MSH, its proposed effects on inflammatory signaling, gut and skin research, available laboratory and animal evidence, community-reported oral, topical and injectable protocols, safety concerns and what to track. Human evidence and online claims will remain clearly separated.

Explore cagrilintide through SubZ’s research-first approach. This file examines how the long-acting amylin analogue works, what human trials have studied, protocols used in clinical research, side effects, safety considerations and what to track. It also separates evidence for cagrilintide alone from results involving its investigational combination with semaglutide, known as CagriSema.

Explore Tesamorelin through SubZ’s research-first approach. This file examines the growth hormone–releasing factor analog, how it stimulates pituitary GH and IGF-1 signaling, its FDA-approved use for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, additional visceral and liver-fat research, clinical dosing, side effects, safety warnings and what to track. Approved evidence and broader online claims will remain clearly separated.

Explore GHK-Cu through SubZ’s research-first approach. This file examines what the copper-binding peptide is, how it may influence tissue repair, skin, hair and inflammation, what human and laboratory research has studied, route-specific considerations, safety, protocols reported in research and what to track. Evidence levels will be clearly separated from community claims.

Explore BPC-157 through SubZ’s research-first approach. This file examines what the synthetic 15-amino-acid peptide is, its proposed mechanisms, animal and limited human research involving tissue repair, pain and gastrointestinal health, community-reported protocols, safety concerns and what to track. Evidence levels will be clearly separated from online claims.

Explore TB-500 through SubZ’s research-first approach. This file separates the seven-amino-acid TB-500 fragment from full-length thymosin beta-4 and examines proposed tissue-repair mechanisms, available animal and human evidence, community-reported injectable protocols, safety concerns and what to track. Evidence for TB-500 itself will remain separate from studies using thymosin beta-4.

Explore SS-31, also known as elamipretide, through SubZ’s research-first approach. This file examines how the mitochondria-targeting tetrapeptide interacts with cardiolipin, what human trials have studied, approved versus investigational uses, clinical and community protocols, side effects, safety considerations and what to track. Evidence will remain tied to the exact product, condition and route studied.

Explore MOTS-c through SubZ’s research-first approach. This file examines the 16-amino-acid mitochondrial-derived peptide, its proposed roles in cellular energy sensing, glucose metabolism and exercise adaptation, available animal and emerging human research, community-reported injectable protocols, safety concerns and what to track. Evidence levels will remain clearly separated from online claims.

Explore Selank through SubZ’s research-first approach. This file examines the synthetic seven-amino-acid peptide, its proposed effects on anxiety, stress and GABA-related signaling, limited human research, intranasal and community-reported injectable protocols, safety concerns and what to track. Evidence from laboratory studies, small clinical reports and online claims will remain clearly separated.

Explore Semax through SubZ's research-first approach. This file examines the synthetic heptapeptide originally developed from an ACTH fragment, its proposed effects on cognition, neuroprotection and BDNF-related signaling, available human and animal research, intranasal and community-reported injectable protocols, safety considerations and what to track. Evidence from clinical studies, laboratory research and community claims will remain clearly separated.

Explore Epitalon through SubZ’s research-first approach. This file examines the synthetic tetrapeptide linked to pineal and aging research, proposed effects on telomerase, circadian signaling and cellular stress, available human, animal and laboratory evidence, community-reported protocols, safety concerns and what to track. Longevity claims and established evidence will remain clearly separated.

Explore AOD-9604 through SubZ’s research-first approach. This file examines the modified C-terminal growth-hormone fragment, its proposed effects on fat metabolism, animal and human obesity research, why later trials failed to demonstrate meaningful weight loss, research and community protocols, safety concerns and what to track. Growth-hormone-fragment claims and established evidence will remain clearly separated.

Explore Wolverine through SubZ’s research-first approach. This blend file uses the common 1:1 formulation of BPC-157 10 mg and TB-500 10 mg. It examines each component, why they are combined in community recovery protocols, available laboratory, animal and emerging human research, blend-ratio limitations, community-reported protocols, safety concerns and what to track. Individual-compound evidence and fixed-blend claims will remain clearly separated.

Explore KLOW through SubZ’s research-first approach. This blend file uses GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg. It examines why these compounds are combined in community skin, gut and recovery protocols, component-level evidence, fixed-ratio limitations, community-reported protocols, safety concerns and what to track. Individual-compound evidence and KLOW blend claims will remain clearly separated.